Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Buy at Wall Street Zen
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday. Other analysts also recently issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price objective on shares of […]
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday. Other analysts also recently issued research reports about the stock. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price objective on shares of […]
